Skip to main content

Drug Interactions between heparin and oritavancin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

heparin oritavancin

Applies to: heparin and oritavancin

CONTRAINDICATED: Use of oritavancin may interfere with the therapeutic monitoring of heparin therapy. Oritavancin can bind to and prevent the action of the phospholipid reagents that activate coagulation in commonly used laboratory coagulation tests. Administration of oritavancin has been shown to artificially prolong the activated partial thromboplastin time (aPTT) for up to 120 hours and activated clotting time (ACT) for up to 24 hours following a single 1200 mg dose. Oritavancin does not affect the coagulation system in vivo, however.

MANAGEMENT: Use of intravenous unfractionated heparin is contraindicated for 120 hours (5 days) after oritavancin administration. For patients who require aPTT monitoring within 120 hours of oritavancin dosing, a non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT monitoring may be considered.

References

  1. (2014) "Product Information. Orbactiv (oritavancin)." The Medicines Company

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer